Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 4, 2021, reports a material corporate event under Item 8.01. The filing states that on August 5, 2021, Phathom issued a press release announcing the unexpected death of Tadataka Yamada, M.D., the company’s founder and chairman of the Board of Directors.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, operating, or other financial metrics. It is not an earnings or financial results filing.
Material Changes Versus the Prior Period
The filing reports a change in the company’s leadership circumstances resulting from the unexpected passing of its founder and board chairman. It does not describe any financial or operating-period comparison.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or business outlook is provided.
- The unexpected death of the founder and board chairman is the principal unusual and potentially material event disclosed.
- The filing does not describe succession plans, changes to board composition, management responsibilities, strategic direction, or expected business impact.
- Exhibit 99.1 is the related press release issued August 5, 2021.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the company’s full announcement and any commentary regarding succession or governance.
- Confirm the applicable event and filing dates, as the Form 8-K header identifies August 4, 2021, while the press release and signature date are August 5, 2021.
- Monitor subsequent SEC filings for board changes, appointment of a new chair, succession actions, or other effects on corporate governance and strategy.